New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
04:55 EDTBCR, BCR, ISIS, ISIS, TRVN, TRVN, SGEN, SGEN, ONCS, ONCS, KBIO, KBIO, GNMK, GNMK, LXRX, LXRX, ACAD, ACAD, EXAM, EXAMNeedham to hold a conference
Life Sciences Conference is being held in New York on April 8-9.
News For BCR;ACAD;LXRX;GNMK;KBIO;ONCS;SGEN;TRVN;ISIS;EXAM From The Last 14 Days
Check below for free stories on BCR;ACAD;LXRX;GNMK;KBIO;ONCS;SGEN;TRVN;ISIS;EXAM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
16:31 EDTSGENSeattle Genetics sees FY14 revenue from ADCETRIS $160M-$170M
Subscribe for More Information
16:29 EDTSGENSeattle Genetics reports Q2 EPS (14c), consensus (22c)
Subscribe for More Information
July 30, 2014
11:14 EDTEXAMHigh option volume stocks
High option volume stocks: EXAM ASML EWY TQNT NFX RFMD RATE BPI GALT ZLTQ
July 29, 2014
18:35 EDTEXAMOn The Fly: After Hours Movers
Subscribe for More Information
16:38 EDTEXAMExamWorks sees Q3 revenue $194M-$200M, consensus $180.26M
Subscribe for More Information
16:37 EDTEXAMExamWorks raises FY14 revenue growth view to 22.5%-24.5%
Subscribe for More Information
16:34 EDTEXAMExamWorks reports Q2 EPS 9c, consensus 4c
Reports Q2 revenue $196.4M, consensus $184.52M.
09:45 EDTBCRC.R. Bard downgraded to Underperform from Neutral at BofA/Merrill (pre-open)
07:45 EDTGNMKGenMark remains top pick after strong Q2, says Canaccord
Canaccord said GenMark remains their top pick following the company's strong Q2 results, citing its strong near term execution and its long term investing, which should lead to a platform offering across a suite of infectious disease tests. Canaccord has a Buy rating with a $17 price target on GenMark.
July 28, 2014
16:11 EDTGNMKGenMark sees Q2 revenue $6.6M, consensus $4.79M
During the quarter, 31 additional XT-8 analyzers were placed in end user laboratories, resulting in a total installed base of 475 analyzers within the U.S. market.
16:09 EDTKBIOKaloBios regains global rights to KB001-A, completes enrollment in phase 2 study
Subscribe for More Information
16:00 EDTKBIOKaloBios trading halted, pending news
July 24, 2014
17:36 EDTBCRC.R. Bard raises FY14 EPS view to $8.25-$8.35 from $8.20-$8.30
Subscribe for More Information
17:34 EDTBCRC.R. Bard sees Q3 EPS $2.07-$2.11, consensus $2.09
Subscribe for More Information
16:25 EDTBCRC.R. Bard reports Q2 adjusted EPS $2.06, consensus $2.01
Subscribe for More Information
July 23, 2014
10:24 EDTTRVNTrevena management to meet with Jefferies
Subscribe for More Information
10:23 EDTTRVNTrevena management to meet with Needham
Subscribe for More Information
July 21, 2014
07:11 EDTONCSInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
July 17, 2014
07:10 EDTISISIsis Pharmaceuticals begins Phase 2 study of candidate for high lipoprotein(a)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use